UT-MD Anderson Cancer Center: Adagrasib Effective for Patients With KRAS G12C-Mutant Lung Cancer and Untreated Brain Metastases
June 17, 2023
June 17, 2023
HOUSTON, Texas, June 17 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Targeted therapy is first KRAS G12C inhibitor to demonstrate intracranial responses
* * *
Researchers from The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing cancer growth not only within the lungs but also in brain metastases for patients wi . . .
* * *
Targeted therapy is first KRAS G12C inhibitor to demonstrate intracranial responses
* * *
Researchers from The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing cancer growth not only within the lungs but also in brain metastases for patients wi . . .